Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Pancreatic Neoplasms 6Small Cell Lung Carcinoma 4Cholangiocarcinoma 4Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic Cancer Metastatic 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Locally Advanced Pancreatic Cancer 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

surufatinib 1pembrolizumab 1lenvatinib 1donafenib 1Thyrotropin Alfa 1Sorafenib 1Injections 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Differentiated Thyroid Cancer × surufatinib × Clear all
NCT05989425 2023-08-14

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Fudan University

Phase 2 Recruiting
32 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡